Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
Location: United States, California, San Diego
Employees: 501-1000
Total raised: $260M
Founded date: 2009
Investors 5
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | Ally Bridg... | ally-bridg... |
| 06.11.2022 | Hercules C... | htgc.com |
| - | ShareLink ... | sharelink-... |
| - | Canaan Par... | canaan.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 08.10.2019 | - | $25M | - |
| 29.11.2016 | - | $75M | - |
| 03.05.2016 | - | $10M | - |
| 10.04.2016 | - | $150M | Ally Bridg... |
Mentions in press and media 19
| Date | Title | Description |
| 08.03.2024 | CAR T-Cell Therapy Market Set for Healthy Growth after COVID19 Pandemic Top Players Industry Trends and Forecast 2032 | CHICAGO, UNITED STATES, March 8, 2024 /EINPresswire.com/ -- Astute Analytica, a leading provider of market research and analysis, released its highly anticipated Market Analysis Report on the Global 𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭. This comprehen... |
| 19.02.2023 | Sorrento Posts Form 8937 to Supplement its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, "Scilex") | SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. SRNE "Sorrento"))) today posted an IRS Form 8937 (the "Form 8937") to supplement its previously issued "Frequently Asked Questions" docum... |
| 25.03.2022 | Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connect... | PALO ALTO, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and... |
| 20.01.2022 | SORRENTO THERAPEUTICS ANNOUNCES COVISHIELD (STI-9167), A BROAD-SPECTRUM NEUTRALIZING ANTIBODY, POTENTLY NEUTRALIZES OMICRON AND OMICRON (+R346K) VARIANTS OF SARS-COV-2 | SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the release of new data on the Omicron variant neutralizing antibody (nAb) STI-9167, COVISHIELD, an advanced stage ant... |
| 16.04.2020 | Covid-19 vaccine tracker updated to include GSK/Sanofi collaboration | By Jeff Craven Currently, there are no FDA-approved therapies or vaccines for SARS-CoV-2, the virus that causes Covid-19. The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes... |
| 09.04.2020 | Covid-19 Tracker updates vaccine candidates | By Jeff Craven On March 11, the World Health Organization classified the Covid-19 outbreak as a pandemic. The disease has reached nearly every country, infecting hundreds of thousands of people and killing thousands. Curr... |
| 18.06.2019 | Sorrento Valley startup raises $3M following pitch competition win — all from local investors | - |
| 22.08.2017 | Sorrento Therapeutics Invests In New Company, Celularity | San Diego-based biopharmaceuticals developer Sorrento Therapeutics announced on Monday that it has invested in a newly former company, Celularity, focused on treatment of cancer, inflammatory and degenerative diseases, and functional regene... |
| 14.04.2017 | Sorrento drops 39% before Easter after shares offering | San Diego biotech Sorrento, which spent much of the last 12 months warring with its minority stakeholder Wildcat, won’t be finding many golden eggs this weekend after being the biggest biotech stock loser ahead of today’s market close. The ... |
| 16.03.2017 | Aerpio Pharmaceuticals Raises $40 Million | Aerpio Pharmaceuticals, Inc. (the “Company”), a biopharmaceuticalcompany focused on advancing first-in-class treatments for ocular diseases, today announced thesuccessful completion of its reverse merger transaction with Aerpio Therapeutics... |
Show more